



Handwritten signature/initials

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Ulrich KLAR et al. : Group Art Unit.: 1626
Serial No.: 10/631,011 : Examiner: Taofiq A. Solola
Filed: July 31,2003 :
Title: EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR
PHARMACEUTICAL USE

REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


SIR:

In response to the Office Action mailed on April 26, 2005, applicants elect with traverse Group II, claims 9-11. As species, applicants elect Example ELE 33. Attached is a page illustrating the structure of ELE 33 for the purpose of identifying the various substituents. The traversal is on the grounds that the patent office has not established that it would pose an undue burden to examine the full scope of the claimed invention.

Additionally, applicants bring the attention of the Examiner to MPEP § 821.04, Rejoinder, which states that "if the elected invention is directed to the product and the claims directed to the product are subsequently found patentable, process claims [both process of making and using] which either depend from or include all the limitations of the allowable product will be rejoined." If the restriction requirement is maintained at this point, rejoinder of the non-elected claims that are rejoinable is respectfully requested at the proper time in accord with the rejoinder provisions of the MPEP.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Csaba Henter, Reg. No. 50,908
Anthony J. Zelano, Reg. No. 27,969

Attorneys for Applicants


MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: 703-812-5331
Facsimile: 703-243-6410

Filed: June 15, 2005



ELE33

4-(3-(2H8-Ab)_x-sulfanyl-2,5-dioxo-pyrrolidin-1-yl)-butanoic acid 4-(1S,3S,7S,10R,11S,12S,16R)-[10-allyl-7-hydroxy-8,8,12,16-tetramethyl-3-(2-methyl-benzothiazol-5-yl)-5,9-dioxo-4,17-dioxo-bicyclo[14.1.0]heptadec-11-yloxycarbonyloxymethyl]-2-nitro-phenyl ester



x describes the mean number of effector molecules coupled to the antibody. The range might be $x=2$ to $x=0.05$, more typically $x=1$ to $x=0.1$.